VIVUS (VVUS) Trades Higher Following Positive Avanafil Phase 3 for ED (PFE)
Tweet
Share
E-mailGet Alerts VVUS Hot Sheet
Join SI Premium – FREE
VIVUS, Inc. (Nasdaq: VVUS) is trading higher pre-market after reporting strong results for its Phase 3, placebo-controlled clinical trial of the investigational drug avanafil for the treatment of erectile dysfunction (ED) in patients following a radical prostatectomy. Shares are up about 51 cents to $8.90, or 6 percent.
VIVUS said that avanafil "met all primary endpoints by demonstrating improvement from baseline in erectile function as measured by the Sexual Encounter Profile (both SEP2 and SEP3) and improvements in the International Index of Erectile Function (IIEF)."
Continuing, "The results of the TA-303 study are not required for the avanafil New Drug Application (NDA), but the final study report will be submitted to the FDA upon completion."
VIVUS said that it expects to file the NDA for avanafil in Q211.
Notably, Pfizer (Nasdaq: PFE), which manufactures Viagra, is slightly lower ahead of the market.
VIVUS said that avanafil "met all primary endpoints by demonstrating improvement from baseline in erectile function as measured by the Sexual Encounter Profile (both SEP2 and SEP3) and improvements in the International Index of Erectile Function (IIEF)."
Continuing, "The results of the TA-303 study are not required for the avanafil New Drug Application (NDA), but the final study report will be submitted to the FDA upon completion."
VIVUS said that it expects to file the NDA for avanafil in Q211.
Notably, Pfizer (Nasdaq: PFE), which manufactures Viagra, is slightly lower ahead of the market.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
- FDA grants Nuvation Bio fast track status for brain cancer drug
- Ionis to present olezarsen and ION775 data at ESC Congress 2026
Create E-mail Alert Related Categories
FDA, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
